🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

UNC A031702 startup today. Thanks to Andrea Apolo, M.D. for designing this #ICONIC study for our UNC Urologic Oncology Program patients with #rareGUcancers led by UNC PI Tracy Rose. Alliance for Clinical Trials in Oncology @morr316 leading the way for patients with #GUcancers.

Do you love #walks? Why not walk and raise money and awareness for #bladdercancer? You can walk anytime and anywhere on May 1, 2021 and then join us for an awesome virtual event! Register today at bcan.org/walk-to-end-bl…! Mary Weinstein Dunn Tracy Rose

The two week countdown begins! 🔊 It's easier than ever to get involved in this year’s virtual Walk to End Bladder Cancer. Whether you're joining a team or walking as an individual, your participation makes a difference. Join us on Saturday, May 1: ow.ly/EPLR50E1x0e

10,000 retweets & we'll play Baby Shark for every Memphis Redbirds player's walk-up song.

Thrilled our study of chemo-immunotherapy in MIBC was published in JCO this week! My ASCO AACR #Vail workshop protocol and a great collaboration between UNC Lineberger and DCI Center for Prostate & Urologic Cancers - thanks to all for the tremendous support along the way, most especially Matt Milowsky

Should I order a PET scan? Integrating molecular imaging into urologic oncology clinical practice: Current approaches and future opportunities Marc A. Bjurlin Tracy Rose Thomas Hope Michael Gorin, M.D. #AUA22 Room 207, Course 002IC 730-930am

Congratulations to three UNC Lineberger fellows, Fernando Diaz, MD, MD, Joannie M. Ivory, MD, MSPH, MHS, MSPH, MD, and Jacob N. Stein, MD, MPH, on receiving the Conquer Cancer, the ASCO Foundation Young Investigator Award at #ASCO22.

Favourer slide of #ASCO2022 Matt Milowski showing pCR rates for chemo vs IO vs chemo/IO in MIBC. They all look the same. Is single agent pembro really as good as ddMVAV? is comparing different regimens fair? Is this a useful endpoint? What does it mean for the IO/chemo trials?